RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 111-121
  • Retirement: pushing the pause/restart buttons

    Kiplinger's Personal Finance Working past 66 may not be everyone's idea of a dream "retirement," but for many baby-boomers, it could represent the future. A 2013 Wells Fargo survey showed that one-third of respondents expect to work until "at least 80"...
  • Investing: For growth, look to Israel

    Kiplinger's Personal Finance With more start-up businesses per capita than anywhere in the world, Israel is brimming with tantalizing investment prospects. Moreover, many Israeli stocks trade in the U.S, making it simple for Americans to buy in....
  • Baxter has no plans for inversion with spinoff

     Baxter has no plans for inversion with spinoff
    While its peers in the northern suburbs and around the pharmaceutical industry have been lining up foreign mergers to help sidestep U.S. taxes, Baxter International said Thursday it has no plans to jump on the bandwagon. The Deerfield-based health...
  • AbbVie to buy drugmaker Shire in nearly $55 billion deal

    AbbVie to buy drugmaker Shire in nearly $55 billion deal
    AbbVie Inc. has inked a nearly $55 billion deal to acquire drugmaker Shire PLC, the companies announced in a joint statement Friday morning. The deal, the largest of a year filled with merger and acquisition activity, will allow the North Chicago-...
  • AbbVie to Buy Shire for $54.8 billion in biggest inversion

    AbbVie to Buy Shire for $54.8 billion in biggest inversion
    AbbVie Inc. is buying Shire for nearly $55 billion, the largest deal in a year filled with merger and acquisition activity, and the latest example of companies taking foreign addresses to cut taxes. The deal will allow North Chicago-based pharmaceutical...
  • AbbVie-Shire deal puts more pressure on Congress to overhaul tax code

    A massive pharmaceutical merger that will send the headquarters of a major U.S. drug maker overseas ramps up pressure on Congress to curtail the ability of companies to shelter foreign earnings. Illinois drug maker AbbVie Inc. said Friday that it...
  • AbbVie to buy drugmaker Shire for $55 billion

     AbbVie to buy drugmaker Shire for $55 billion
    AbbVie Inc. signed a nearly $55 billion deal to acquire drugmaker Shire PLC early Friday, a move that will allow it to substantially cut its corporate tax bill by moving its legal address to the United Kingdom. The deal, announced by both companies in a...
  • Allergan to slash workforce by 1,500

    Allergan to slash workforce by 1,500
    Botox maker Allergan Inc. said Monday that it will cut 1,500 employees, most of them in Southern California, in a cost-cutting effort the Irvine company hopes will help it fight off a hostile takeover bid by a Canadian rival. Stung by criticism that it'...
  • AbbVie forced to retract claims of Shire investor support

    AbbVie forced to retract claims of Shire investor support
    AbbVie Inc. CEO Richard Gonzalez has landed in a bit of hot water for statements he made to certain newswires and U.K. press on Tuesday regarding shareholder support for his company's takeover bid for Shire Plc. The North Chicago-based pharmaceutical...
  • Shire confirms in talks with AbbVie on takeover bid

    Shire confirms in talks with AbbVie on takeover bid
    Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie's takeover bid for the Dublin-based maker of drugs for rare diseases. Shire, in a release, said it would provide a further update "when appropriate." It...
  • Abbott to sell generics in major markets to Mylan for $5.3 billion

    Abbott to sell generics in major markets to Mylan for $5.3 billion
    Abbott Laboratories has agreed to sell its specialty and branded generic pharmaceutical business in developed markets to Pennsylvania-based Mylan Inc. in an all-stock transaction valued at about $5.3 billion. The deal, which will give Abbott a roughly...